f Hypoxia-inducible factors 1 and 2 (HIF-1 and -2) control oxygen supply to tissues by regulating erythropoiesis, angiogenesis and vascular homeostasis. HIFs are regulated in response to oxygen availability by prolyl-4-hydroxylase domain (PHD) proteins, with PHD2 being the main oxygen sensor that controls HIF activity under normoxia. In this study, we used a genetic approach to investigate the endothelial PHD2/HIF axis in the regulation of vascular function. We found that inactivation of Phd2 in endothelial cells specifically resulted in severe pulmonary hypertension (ϳ118% increase in right ventricular systolic pressure) but not polycythemia and was associated with abnormal muscularization of peripheral pulmonary arteries and right ventricular hypertrophy. Concurrent inactivation of either Hif1a or Hif2a in endothelial cell-specific Phd2 mutants demonstrated that the development of pulmonary hypertension was dependent on HIF-2␣ but not HIF-1␣. Furthermore, endothelial HIF-2␣ was required for the development of increased pulmonary artery pressures in a model of pulmonary hypertension induced by chronic hypoxia. We propose that these HIF-2-dependent effects are partially due to increased expression of vasoconstrictor molecule endothelin 1 and a concomitant decrease in vasodilatory apelin receptor signaling. Taken together, our data identify endothelial HIF-2 as a key transcription factor in the pathogenesis of pulmonary hypertension.
E
ndothelial cells (ECs) provide barrier, transport, synthetic, and metabolic functions at the interface of blood and adjacent tissue, and they play a central role in the organism's response to hypoxia, as they regulate vascular tone, immune responses, hemostasis, and angiogenesis. Central mediators of hypoxia adaptation are hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2), pleiotropic heterodimeric basic helix-loop-helix transcription factors that regulate erythropoiesis, angiogenesis, vascular homeostasis, energy metabolism, and other oxygen-sensitive biological processes (1) . HIF activity is controlled by O 2 -, iron-, and ascorbatedependent dioxygenases, also known as prolyl-4-hydroxylase domain-containing proteins 1 to 3 (PHD1 to PHD3), which use 2-oxoglutarate (2OG) as the substrate for the hydroxylation of specific proline residues within the oxygen-sensitive HIF-␣ subunit, PHD2 being the main oxygen sensor that regulates HIF activity under normoxia (2) . The hydroxylation of HIF-␣ permits binding to the von Hippel-Lindau (VHL)-E3 ubiquitin ligase complex and results in proteasomal degradation of HIF-␣ subunits (3) . When prolyl-4-hydroxylation is inhibited, e.g., in the absence of molecular oxygen or ferrous iron, HIF-␣ is no longer degraded and translocates to the nucleus, where it dimerizes with ARNT, the constitutively expressed HIF-␤ subunit, and increases the transcription of oxygen-regulated genes (4) .
In humans, genetic mutations in the PHD/HIF/VHL axis have been associated with multiple vascular pathologies. VHL germ line mutations result in a pleomorphic familial tumor syndrome, characterized by the development of highly vascularized tumors, which include central nervous system (CNS) and retinal hemangioblastomas, renal cell cancer, and pheochromocytomas (5) . Furthermore, homozygosity for a hypomorphic VHL allele (R200W), which impairs the cell's ability to efficiently degrade HIF-␣ under normoxia, is associated with the development of polycythemia, pulmonary hypertension, and vertebral hemangiomas and increased incidence of cerebral vascular events (6, 7) . Polycythemia and pulmonary hypertension have also been associated with rare activating mutations in the HIF2A locus (8) . The critical role of HIF signaling in vascular development and pathogenesis is furthermore strongly supported by genetic studies with mice. For example, global inactivation of either Hif1a or Arnt resulted in embryonic lethality due to abnormal vascular development (9, 10) , whereas Hif2a inactivation led to defects in embryonic vascular remodeling and other pathologies, which were genetic background dependent (11) (12) (13) (14) . Conversely, activation of HIF signaling via Phd2 germ line ablation resulted in severe placental and heart defects that led to embryonic demise between embryonic days 12.5 and 14.5 (15) , whereas global Phd2 inactivation in adults led to excessive vascular growth and angiectasis in multiple organs (16) . The promotion of vascular pathology as a result of PHD inactivation is a major clinical concern, as several HIF-activating PHD-inhibiting compounds are currently in phase 2 and 3 clinical trials for the treatment of renal anemia (17) .
While genetic studies have found divergent functions for HIF-1 and HIF-2 in tumor angiogenesis, metastasis, maintenance of lung endothelial barrier, and postischemic renal inflammation (18) (19) (20) (21) (22) (23) , relatively little is known about the role of endothelial PHDs in vascular homeostasis in the adult. To investigate the role of the endothelial PHD2/HIF axis in vascular homeostasis, we used a genetic approach and ablated Phd2 individually or in conjunction with either Hif1a or Hif2a by Cre-loxP-mediated recombination. We found that loss of endothelial PHD2 induced pulmonary arterial hypertension and vascular remodeling in a HIF-2-dependent, and not HIF-1-dependent, fashion. We furthermore show that endothelial HIF-2 is required for the development of hypoxia-induced pulmonary hypertension and thus demonstrate that genetic manipulations of HIF-2 signaling in ECs specifically are sufficient to alter pulmonary vascular responses to hypoxia. Taken together, our findings identify endothelial HIF-2 as a potential therapeutic target for the treatment of pulmonary hypertension. Furthermore, our data have implications for the clinical use of PHD inhibitors as erythropoiesis-stimulating agents (ESA) in patients with advanced chronic kidney disease, who are predisposed to the development of pulmonary hypertension (24) .
MATERIALS AND METHODS
Generation of mice, genotyping, and animal procedures. The generation and genotyping of Phd2, Hif1a, and Hif2a (also known as Epas1) 2-lox alleles have been described previously (10, 25, 26) . For the activation or inactivation of PHD2, HIF-1␣, and HIF-2␣ in ECs, VE-cadherin (Cdh5)-cre transgenic mice were used (27) .
Transthoracic echocardiography was conducted using a Vevo 770 high-resolution image system (VisualSonics, Toronto) (28) . Right ventricular systolic pressure (RVSP) was measured invasively by inserting a 1.4F Mikro-tip catheter transducer (Millar Instruments, Houston, TX) into a surgically exposed right internal jugular vein, as described elsewhere (29) . Systolic blood pressure (SBP) was measured in conscious mice at room temperature using a tail cuff monitor (BP-2000 BP analysis system; Visitech System). An animal hypoxia chamber from Biospherix, Ltd., was used for in vivo hypoxia experiments. Bone marrow transplantation was performed as previously described (20) , and chimeric mice were subjected to hypoxia 5 weeks following transplantation. For pharmacological HIF activation, HIF prolyl-4-hydroxylase inhibitor GSK1002083A (GlaxoSmithKline) was dissolved in 1% methylcellulose and administered by oral gavage at a dose of 60 mg/kg of body weight (BW). Complete blood counts were determined with a Hemavet 950 analyzer (Drew Scientific). Blood glucose levels were measured with the iSTAT portable clinical analyzer (Abbott portable handheld clinical analyzers). All procedures involving mice were performed in accordance with NIH guidelines for the use and care of live animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of Vanderbilt University and the University of Kansas.
DNA, RNA, and protein analyses. DNA and RNA were isolated and used for genomic or real-time PCR analysis as previously described (20) ; mouse primer sequences used are shown in Table S1 in the supplemental material. For the detection of HIF-1␣ and HIF-2␣ by immunoblotting, nuclear protein extracts were prepared and analyzed as previously described (30) .
Morphological analysis. For the morphological analysis, agarose-inflated lungs were fixed with 10% buffered formalin. Macrophage infiltration and cell proliferation were assessed with a monoclonal rat anti-F4/80 antibody and a polyclonal rabbit anti-Ki67 antiserum, respectively (Abcam, Inc.). To assess vessel muscularization of peripheral blood vessels, an anti-␣-smooth muscle actin (anti-␣SMA) antibody (Boster Bio) was used. For all morphological quantifications, 10 random visual fields were analyzed per lung section at a magnification of ϫ200 using ImageJ software (http://rsbweb.nih.gov/ij).
Statistical analysis.
All data are reported as mean values Ϯ standard errors of the means (SEM). Statistical analyses were performed with Prism 5.0b (GraphPad Software, La Jolla, CA). Univariate analysis was done using the Student t test, and a two-sided significance level of 5% was considered statistically significant.
RESULTS
Generation of mice with EC-specific inactivation of Phd2. To investigate the role of endothelial PHD2 in the pulmonary vasculature, we crossed Cdh5-cre transgenic mice (27) to mice homozygous for the conditional Phd2 allele (26) , hereafter designated ePhd2 Ϫ/Ϫ mutants. Cdh5-cre is expressed in Ͼ90% of pulmonary ECs, as previously shown by our laboratory (20) , and genomic PCR analysis confirmed efficient excision of the floxed Phd2 sequence (Fig. 1A) . Accordingly, Phd2 transcript levels showed a 2.1-fold reduction in total lung homogenates from ePhd2 Ϫ/Ϫ mu-A.
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Ldha Glut1 Ϫ/Ϫ mutants and Cre Ϫ littermate controls (n ϭ 7; P ϭ 0.02). (B) (Top) Immunoblot analysis of HIF-1␣ and HIF-2␣ in lung nuclear extracts isolated from ePhd2 Ϫ/Ϫ and Cre Ϫ mice. Ponceau S staining was used to assess for equal protein loading. Nuclear kidney extracts from a mouse treated with an oral PHD inhibitor served as a positive control (Ctrl). (Bottom) Pgk1, Ldha, and Glut1 mRNA levels in lungs from mutant mice compared to those from Cre Ϫ littermate controls (n ϭ 6). Bars represent mean values Ϯ SEM. *, P Ͻ 0.05; **, P Ͻ 0.01. tants (n ϭ 7; P ϭ 0.02) (Fig. 1A) . EC-specific inactivation of Phd2 resulted in significant HIF-2␣ accumulation in whole lung homogenates, whereas a change in HIF-1␣ levels was not apparent (Fig. 1B) . However, since glycolytic genes are predominantly regulated by HIF-1 and not HIF-2 (1), increased HIF-1 activity was suggested by the expression of Pgk1 and Ldha being increased 2.2-and 2.1-fold, respectively (n ϭ 4) (Fig. 1B) . Glut1 was increased 1.8-fold (Fig. 1B) .
Inactivation of endothelial Phd2 results in pulmonary hypertension. While birth rates were not significantly different from the frequencies expected based on Mendelian genetics, ePhd2 Ϫ/Ϫ mutants had a significantly shorter life span ( Fig. 2A) . By 6 weeks of age, total body weight (BW) was reduced by ϳ30% (P ϭ 0.007; n ϭ 5 or 6) (Fig. 2B) . While the PHD2/HIF axis is important in the regulation of erythropoiesis and glucose homeostasis (17, 31) , ECspecific Phd2 inactivation did not produce polycythemia or abnormalities in blood glucose levels ( Fig. 2C ; see also Fig. S1 in the supplemental material). In contrast to findings for the kidneys and spleen (see Fig. S1B ), ePhd2 Ϫ/Ϫ mutants displayed a 29% increase in heart weight/BW ratio (P ϭ 0.0023; n ϭ 8 or 9) and a 45% increase in lung weight/BW ratio, raising the possibility that ePhd2 Ϫ/Ϫ mutants were predisposed to the development of congestive heart failure (P ϭ 0.038; n ϭ 4 to 6) (Fig. 2B) . However, comparison of wet to dry lung weights was not consistent with elevated pulmonary water content (Fig. 2B) .
Given the increase in heart weights, we next performed cardiac Ϫ/Ϫ mice and Cre Ϫ controls (n ϭ 4 to 6). Bars represent mean values Ϯ SEM. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001. sonography in 10-to 12-week-old mice. Although we did not find significant changes in heart rate and parameters of left ventricular (LV) function (normal fractional shortening), ePhd2 Ϫ/Ϫ mutant mice displayed significant increases in pulmonary artery (PA) area (3.58 Ϯ 0.27 mm 2 versus 2.49 Ϯ 0.13 mm 2 in controls; n ϭ 5 to 7; P ϭ 0.0098) and right ventricular (RV) stroke volume (64 Ϯ 6 mm 3 versus 46 Ϯ 4 mm 3 in controls; n ϭ 5 to 7; P ϭ 0.04), which were associated with a reduction in PA acceleration time (PAAT) (13.93 Ϯ 2.10 ms versus 22 Ϯ 1.22 ms in controls; n ϭ 5 to 7; P ϭ 0.01) ( Table 1) . Furthermore, deletion of endothelial Phd2 resulted in right ventricular hypertrophy (RVH), which was assessed by the Fulton index, calculated as the weight ratio between RV and LV plus septum; ePhd2 Ϫ/Ϫ mice exhibited an 86% increase in the Fulton index compared to that of the controls (P ϭ 0.0004; n ϭ 5 to 7) (Fig. 2D ). Taken together, anatomic and echocardiographic findings were consistent with RV remodeling, which is likely to be secondary to pulmonary hypertension. To assess PA pressures directly, we next performed right heart catheterization via right jugular vein access and found increased RVSP (54.23 Ϯ 6.93 mm Hg versus 24.84 Ϯ 2.17 mm Hg in controls; P ϭ 0.005, n ϭ 5 or 6), confirming the presence of pulmonary hypertension in ePhd2 Ϫ/Ϫ mutants ( Fig. 2D) . A difference in SBP between the mutants and controls was not found (Fig. 2D) .
Despite RVH and the significant increase in RVSP, morphological analysis of ePhd2 Ϫ/Ϫ lungs by hematoxylin and eosin (H&E) staining did not demonstrate plexiform or lumen-obliterating lesions, both hallmarks of severe pulmonary hypertension in humans (32) (Fig. 3A) . However, enhanced muscularization of peripheral pulmonary arteries was detected in mutants compared to controls, as indicated by an increase in the number of arteries with diameters of Ͻ100 m that stained positive for ␣SMA (22.1 Ϯ 1.6 versus 7.6 Ϯ 1.5 muscularized vessels/10 high-power fields [HPF] ; n ϭ 5 to 7; P Ͻ 0.0001) (Fig. 3B) . Remarkably, we observed patchy areas of alveolar injury, which exhibited increased ␣SMA expression and F4/80 ϩ cell infiltration in ϳ60% of ePhd2 Ϫ/Ϫ mice (see Fig. S2 in the supplemental material). However, most of the lung parenchyma had normal morphology, and quantification of F4/80 ϩ cells in random optical fields showed no significant difference between mutants and controls (Fig. 3B) . We next examined the expression of proliferation marker Ki67. In ePhd2 Ϫ/Ϫ mutants, we found an ϳ32% reduction in the number of Ki67 ϩ cells in areas of normal lung parenchyma compared to that in controls (P ϭ 0.03; n ϭ 5 to 7) (Fig. 3B) , whereas areas of alveolar injury displayed a significant increase in Ki67 ϩ cells (see Fig. S2 ). In summary, our data demonstrate that inactivation of Phd2 in ECs alone is sufficient to induce pulmonary hypertension, pulmonary vascular remodeling, and RVH in mice. Since Cdh5-Cre activity is not limited to pulmonary endothelium alone and targets all vascular beds, we cannot completely exclude that Phd2 deletion in cardiac ECs by itself has contributed to the development of RVH independently of the elevated pulmonary artery pressures.
Inactivation of HIF-2 but not HIF-1 reverses pulmonary hypertension in ePhd2 ؊/؊ mice. To dissect the contribution of individual HIF homologs to the development of pulmonary hypertension in ePhd2
Ϫ/Ϫ mice, we used the Cdh5-cre transgene to generate mice that were concomitantly deficient for either Phd2 and Hif-1␣ or Phd2 and Hif-2␣, hereafter referred to as either ePhd2 Ϫ/Ϫ Hif1a Ϫ/Ϫ or ePhd2 Ϫ/Ϫ Hif2a Ϫ/Ϫ mutants. As predicted, concurrent inactivation of Phd2 and Hif-1␣ in ECs resulted in a significant accumulation of HIF-2␣, whereas differences in HIF-1␣ levels were not detected between lungs from mutant and control mice (Fig. 4A) . Efficient inactivation of HIF-1 signaling was reflected in the normalization of Pgk1, Ldha, Pdk1, and Pdk3 mRNA levels in lungs from ePhd2 Ϫ/Ϫ Hif1a Ϫ/Ϫ mice compared to those from ePhd2 Ϫ/Ϫ mice ( Ϫ/Ϫ Hif2a Ϫ/Ϫ mice, increased HIF-1 activity in lungs from ePhd2 Ϫ/Ϫ Hif2a Ϫ/Ϫ mice was suggested by a 2.7-fold increase of Pgk1 transcript levels compared to those in controls (P ϭ 0.0012; n ϭ 6) (Fig. 4A) as well as significant induction in the expression of other glycolytic genes (see Fig.  S3 ). In contrast to the findings for ePhd2 Ϫ/Ϫ Hif1a Ϫ/Ϫ mutants, HIF-2␣ levels were no longer elevated (Fig. 4A) .
To determine to what degree individual Phd2/Hif double mutants developed pulmonary hypertension, we performed detailed morphological studies and right heart catheterizations. We found that RVSP was significantly increased in ePhd2 Ϫ/Ϫ Hif1a Ϫ/Ϫ mutants (40.83 Ϯ 2.44 mm Hg versus 23.40 Ϯ 0.54 mm Hg in controls; n ϭ 3 or 4; P ϭ 0.0005), which was associated with the development of significant RVH as indicated by a 2.5-fold increase in the Fulton index (P ϭ 0.0004; n ϭ 4 to 6) (Fig. 4B) . In contrast to findings for the ePhd2 Ϫ/Ϫ Hif1a Ϫ/Ϫ mutants, inactivation of Hif2a reversed RVH and pulmonary hypertension, restoring RVSP and the Fulton index to control levels (Fig. 4B ). In keeping with the results from the hemodynamic measurements, smallvessel muscularization was increased in lungs from ePhd2
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Ϫ/Ϫ mice but not in those from ePhd2 Ϫ/Ϫ Hif2a Ϫ/Ϫ mice (25.5 Ϯ 3.8 muscularized vessels/10 HPF in ePhd2 Ϫ/Ϫ Hif1a Ϫ/Ϫ mutants versus 8.2 Ϯ 1.2 muscularized vessels/10 HPF in controls; n ϭ 4 or 5; P ϭ 0.0057) (Fig. 4C) . Taken together, these findings demonstrate that the activation of HIF-2 but not HIF-1 signaling is responsible for the development of pulmonary hypertension and its associated its associated morphological changes in mice with endothelial Phd2 inactivation. Endothelial HIF-2 is required for the development of hypoxia-induced pulmonary hypertension. Our genetic analysis demonstrated that endothelial HIF-2 was required for the development of pulmonary hypertension in mice with Phd2 inactivation. We next wished to investigate its role in a non-Phd2-deficient genetic background. For this, we chose a model of pulmonary hypertension induced by hypoxia, a common clinical trigger of increased PA pressure. For this purpose, 8-week-old mice that lacked HIF-2␣ in ECs (C57BL/6 background), hereafter referred Ϫ/Ϫ mutants versus 28.82 Ϯ 0.69 mm Hg in controls; n ϭ 4 to 6; P Ͻ 0.0001) and Fulton index (increase by 50%; P ϭ 0.0003) (Fig. 5A) . Furthermore, hypoxia provoked pulmonary vascular remodeling only in Cre Ϫ control mice, which contained significantly higher numbers of muscularized vessels than did eHif2a Ϫ/Ϫ mutants (9.6 Ϯ 1.7 in eHif2a Ϫ/Ϫ mice versus 17.7 Ϯ 1.5 muscularized vessels/10 HPF in controls; n ϭ 4 to 6; P ϭ 0.009) (Fig. 5B) . Collectively, these data provide evidence that endothelial HIF-2 signaling is required for the development of hypoxia-induced pulmonary hypertension in mice that are wild type (WT) for PHD2.
Since VE-cadherin promoter-driven Cre recombinase is ex- pressed in hematopoietic cells (27) , we carried out bone marrow transplantation experiments to exclude the possibility that Hif2a inactivation in hematopoietic cells was contributory. We found that transplantation of eHif2a Ϫ/Ϫ bone marrow cells into lethally irradiated WT mice did not prevent the hypoxia-induced increases in RVSP and the Fulton index compared to those in WT mice transplanted with WT bone marrow (Fig. 5C ). These data suggest that Cdh5-Cre-mediated inactivation of Hif2a in hemato- poietic cells is not sufficient to protect from pulmonary hypertension and furthermore support the notion that endothelial HIF-2 alone is required for the development of pulmonary hypertension induced by chronic hypoxia.
Differential roles for HIF-1 and HIF-2 in the regulation of endothelin 1 and apelin receptor signaling. Because hypoxia regulates endothelin 1 (EDN1) (33, 34), a potent vasoconstrictor, but also apelin (APLN) (35, 36) , a vasodilatory peptide acting through binding to the apelin G-protein-coupled receptor (APLNR), we next assessed the role of the endothelial HIF-2 axis in the regulation of these molecules. Endothelial deletion of Phd2 resulted in a 6.4-fold induction of pulmonary Edn1 mRNA (P ϭ 0.029; n ϭ 8) but not Apln mRNA (Fig. 6) . In contrast, Aplnr was downregulated 2.5-fold in ePhd2 Ϫ/Ϫ mutants (P ϭ 0.037; n ϭ 8) (Fig. 6) . A similar pattern of expression was detected in ePhd2 Ϫ/Ϫ Hif1a Ϫ/Ϫ mice ( Fig. 6) , whereas simultaneous deletion of Hif2a and Phd2 reversed these changes. Specifically, ePhd2 Ϫ/Ϫ Hif2a Ϫ/Ϫ mutants exhibited a 2.3-fold reduction in Edn1 mRNA (n ϭ 6; P ϭ 0.03), a 2.8-fold increase in Apln transcripts (n ϭ 6; P ϭ 0.0002), and no change in Aplnr transcript levels (Fig. 6 ). Similar changes, although not statistically significant, were noted in eHif2a Ϫ/Ϫ mice subjected to chronic hypoxia (Fig. 6) . Cre Ϫ control mice subjected to chronic hypoxia displayed only minor changes in gene expression compared to that in normoxic controls, which is most likely due to physiologic adaptation to prolonged hypoxia, e.g., erythrocytosis.
To investigate the differences between acute and chronic hypoxia, we next examined the effects of acute HIF activation on Edn1 and Apln/Aplnr gene expression in vivo. To model acute hypoxia, we subjected WT mice to 8% O 2 for 48 h and maintained control littermates in room air. Acute hypoxia resulted in 4.3-fold and 1.6-fold upregulation of Edn1 and Apln transcripts, respectively (P ϭ 0.0011 for Edn1; P ϭ 0.08 for Apln; n ϭ 4 or 5), while Aplnr was reduced 4.3-fold (P ϭ 0.0005; n ϭ 4 or 5) (Fig. 7) . We ob- served similar gene expression changes in mice treated with a prolyl-4-hydroxylase inhibitor (PHI) that results in global HIF activation (30) (Fig. 7) . Specifically, treatment with PHI upregulated Edn1 and Apln transcripts 6.6-and 2.6-fold, respectively (P Ͻ 0.0001 for Edn1; P ϭ 0.02 for Apln; n ϭ 4 or 5), while a 3.3-fold reduction was noted for Aplnr (P ϭ 0.002; n ϭ 4 or 5).
While EDN1 and APLN have previously been shown to be HIF regulated in ECs, the suppression of Aplnr in hypoxia conflicted with prior studies proposing that APLNR was induced in hypoxic murine lungs, human stellate cells, and hepatocytes (37, 38) . Because in lungs, both ECs and smooth muscle cells express APLNR, we next examined whether the effects of endothelial HIF-2 activation on Aplnr gene expression in vivo were (i) reproducible and (ii) direct in cultured ECs. To address these questions, we conducted hypoxia experiments (0.5% O 2 for 24 h) with human umbilical cord vein endothelial cells (HUVEC) in the presence or absence of HIF2a or ARNT using a small interfering RNA (siRNA) approach. Although hypoxia resulted in significant downregulation of APLNR mRNA, this response appeared to be HIF independent. In contrast to APLNR, the hypoxic induction of APLN was blunted in HUVEC treated with siRNA against HIF2a (see Fig. S4 in the supplemental material). The discrepancy between these findings and our in vivo data may have resulted from species-related differences or differences in hypoxic signaling between different EC subtypes (vein EC versus arterial EC), or it could be a reflection of context-specific hypoxic gene regulation. Nevertheless, our in vivo data provide strong genetic evidence that activation of endothelial HIF-2 specifically promotes pulmonary vasoconstriction, which associates with dysregulation of EDN1 and APLNR signaling.
DISCUSSION
In the present study, we used a genetic approach to dissect the role of the endothelial PHD2/HIF axis in the regulation of vascular homeostasis. Utilizing different conditional knockout strains, in which Phd2 was inactivated in conjunction with either Hif1a or Hif2a, we obtained experimental evidence that endothelial PHD2 regulates PA pressure through HIF-2 but not HIF-1. We furthermore identified endothelial HIF-2 as a central mediator in the development of hypoxia-induced pulmonary hypertension that is independent of hypoxia-associated polycythemia, and we propose that HIF-2 promotes pulmonary hypertension, at least partially, through the increased expression of vasoconstrictor molecule EDN1 and a concomitant decrease in vasodilatory APLNR signaling.
Pulmonary hypertension resulting from systemic hypoxia or global HIF-2 activation is frequently associated with polycythemia, as kidneys respond to chronic hypoxia or HIF-2 activation with increased erythropoietin (EPO) production (17) , raising the possibility that polycythemia by itself is an important pathogenetic factor in the development of hypoxia/HIF-2-induced pulmonary hypertension. For example, elevations in resting PA pressures with heightened hypoxia responses have been documented (n ϭ 5), ePhd2 Ϫ/Ϫ Hif2a Ϫ/Ϫ (n ϭ 6), and eHif2a Ϫ/Ϫ (n ϭ 4 to 6) mice following chronic normobaric hypoxia (10% O 2 for 4 weeks) and in their corresponding Cre Ϫ littermate controls. 18S was used for normalization. Bars represent mean values Ϯ SEM. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001. for humans with inherited erythrocytosis due to HIF-2 gain-offunction mutations or nontumorigenic VHL mutations (Chuvash polycythemia) (7, (39) (40) (41) . Mice homozygous for the VHL-Chuvash mutation (R200W) spontaneously developed pulmonary hypertension and RVH in a HIF-2-dependent manner (42), a phenotype that was also recapitulated in transgenic mice that carried a HIF-2␣ gain-of-function mutation (G536W) (43) . Since EPOproducing cells are not targeted in ePhd2 Ϫ/Ϫ mice, we were able to dissociate the effects of HIF-2 activation on PA pressure from its effects on erythropoiesis. Our data clearly demonstrate that polycythemia was not required for the development of HIF-2-induced pulmonary hypertension. The fact that HIF-2-induced erythrocytosis does not always associate with pulmonary hypertension, e.g., in humans and mice heterozygous for certain Phd2 mutations (39, 41) , is likely due to tissue-specific differences in the regulation of HIF-2␣ stability or sensitivity to small increases in HIF-2 transcriptional activity.
While our data establish that HIF-2␣ is the critical HIF-␣ homolog regulating pulmonary vascular responses, increased HIF-1␣ expression has been observed in PA-derived medial smooth muscle cells and within human plexiform lesions, a morphological hallmark of idiopathic pulmonary arterial hypertension (IPAH), suggesting that HIF1-dependent signaling may contribute to IPAH-associated proliferative vasculopathy (44) . In mice, global heterozygous Hif1a deficiency dampened pulmonary vascular responses induced by prolonged hypoxia, a finding that suggested a role for HIF-1 in the pathogenesis of hypoxia-induced pulmonary hypertension. However, studies aimed at dissecting the contribution of HIF-1 in a celltype-specific manner generated conflicting results. Inducible deletion of Hif1a in smooth muscle cells using a smooth muscle myosin heavy chain (SMMHC)-CreER T2 transgenic line significantly attenuated hypoxia-induced pulmonary hypertension and the associated remodeling of pulmonary arteries (45) , whereas inactivation of Hif1a achieved by use of a constitutive smooth muscle protein 22 ␣ (SM22a)-Cre transgenic line increased pulmonary vascular tone under both normoxic and hypoxic conditions without inducing vascular remodeling (46) . Because ECs from lungs of patients with IPAH showed evidence of HIF-1 activation and because of HIF-1's involvement in the regulation of energy metabolism, it has been suggested that endothelial HIF-1 may have disease-promoting effects by switching cellular metabolism from oxidative phosphorylation to glycolysis (47) , a process that has been shown to be important for tumor growth. Remarkably, our study found that HIF-1 does not regulate PA pressure in ePhd2 Ϫ/Ϫ mutant mice. Furthermore, although endothelial HIF-1 activity was significantly increased in ePhd2
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Ϫ/Ϫ mutants and was associated with the induction of glycolytic genes, PA pressures were completely normal and pulmonary hypertension did not develop. Consistent with these findings is that the loss of endothelial HIF-2␣ alone was sufficient to confer complete protection from hypoxia-induced pulmonary hypertension. Interestingly, an independent study reported that endothelial HIF-2 deficiency promoted the development of pulmonary hypertension in aged mice. While this report suggested that HIF-2 was protecting from pulmonary hypertension, it is plausible that the development of pulmonary hypertension in aged eHif2a Ϫ/Ϫ animals was secondary to loss of lung endothelial barrier function, which was reported in this model (22) .
Our genetic studies identified ECs as a key cell type in the pathogenesis of hypoxia-induced pulmonary hypertension. Consistent with our findings is a crucial role for ECs in the pathogenesis of IPAH, as shown by studies in which EC-specific deletion of bone morphogenic protein receptor type II (Bmpr2) was sufficient for the induction of pulmonary hypertension in a subset of mice (48) . Conversely, restoration of endothelial BMPR-II expression reversed experimentally induced pulmonary hypertension (49) . Notably, we found that the reversal of pulmonary hypertension in ePhd2 Ϫ/Ϫ Hif2a Ϫ/Ϫ mice was associated with induction of Bmpr2, while treatment with PHI suppressed Bmpr2, suggesting a potential role for HIF-2 in the regulation of BMPR-II levels (see Fig. S5A in the supplemental material). The molecular mechanisms by which loss of BMPR-II in ECs promotes pulmonary hypertension remain ill-defined but may involve a paradoxical increase in EC apoptosis followed by excessive clonal proliferation (32) . Furthermore, a recent study showed that miR-130/301, a key regulator of EC proliferation in both hereditary and acquired forms of pulmonary hypertension, operates under the control of HIF-2 (50). However, we did not find significant alterations in the expression of miR-130a and miR-301a in ePhd2 Ϫ/Ϫ or PHI-treated mice (see Fig. S5B ). Nevertheless, mice with EC-specific Phd2 inactivation did not show a significant hyperproliferative response or obstructive cellular lesions, raising the possibility that certain EC-mediated responses in the context of hypoxia-induced pulmonary hypertension are distinct from those in IPAH.
Hypoxia, among other triggers, promotes sustained vasoconstriction and vascular remodeling by modulating the production of growth factors and vasoactive mediators in ECs (51). For example, EDN1, a small peptide released from ECs, induces potent vasoconstriction upon binding to its receptors on smooth muscle cells. In agreement with the previously established role of EDN1 in hypoxia-induced pulmonary hypertension (52), we found that increased pulmonary Edn1 mRNA levels were associated with the presence of pulmonary hypertension in our genetic models. Although prior studies have shown that Edn1 is coregulated by HIF-1 and HIF-2 (33, 42), we demonstrate that endothelial PHD2 controls the expression of Edn1 via HIF-2. In contrast to the case with EDN1, the HIF-2-dependent suppression of Aplnr was an unexpected finding and suggested that abnormal vasodilatory APLN signaling may have contributed to hypoxia-induced pulmonary hypertension. Given that HIF-2 usually acts as a transcriptional activator and not suppressor (53), HIF-2-dependent suppression of Aplnr transcription is likely to have occurred indirectly. Prior studies with rat cardiomyocytes and adipocytes have shown that the APLNR ligand APLN is HIF-1 inducible (35, 36) . This is in agreement with the increased expression of Apln in ePhd2 Ϫ/Ϫ Hif2 Ϫ/Ϫ mice. However, Apln expression was significantly blunted in ePhd2 Ϫ/Ϫ mutants, which suggested that HIF-2 is likely to suppress APLN synthesis despite the presence of HIF-1␣. Taken together, our findings support a concept where the endothelial PHD2/HIF-2 axis blunts APLN-mediated vasodilatory effects by inhibiting Aplnr expression and by limiting HIF-1-dependent induction of Apln. Consistent with this model are previous studies in which APLN-mediated effects on vascular tone were lost under hypoxic conditions (54) . Furthermore, two genetic APLNR variants (rs11544374 and rs2282623) were associated with a predisposition to high-altitude pulmonary edema, reinforcing the concept that APLNR signaling plays a critical role in hypoxia-induced vascular responses in the lungs (55) .
In summary, we have shown by a genetic approach that activation of HIF-2 signaling in ECs plays a critical role in the pathogenesis of pulmonary hypertension. Our findings justify careful cardiovascular evaluations of patients that participate in clinical trials of HIF-2-activating PHD inhibitors for the treatment of renal anemia (17) . However, pharmacological inhibition of HIF-2 signaling (56, 57) may represent a novel approach for treating pulmonary hypertension.
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